FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W3206757389> ?p ?o ?g. }

• W3206757389 endingPage "iv11" @default.
• W3206757389 startingPage "iv10" @default.
• W3206757389 abstract "Abstract Aims Glioblastoma (GBM) is currently an incurable malignancy with a very poor prognosis for the majority of patients. Many patients undergo debulking surgery, radiotherapy and chemotherapy however therapeutic options are limited, and this can lead to patients sourcing their own treatments. There is some evidence that cannabinoids have the effect of inhibiting GBM tumour growth through a variety of pathways, some of which include CB2 cannabinoid receptor pathway activation. We undertook a patient questionnaire to understand what alternative therapies patients are accessing and why, with a focus on cannabinoid use. Method We undertook a prospective observational questionnaire based qualitative study of 50 … consecutive patients undergoing treatment for glioblastoma at our centre. Results 43 patients responded to our questionnaire. 33% of patients were taking some kind of supplementary therapy with 25% taking cannabis derivatives, mainly CBD oil. There were no clear discriminators amongst our cohort including age or sex when considering the likelihood of taking cannabis derivatives. 6 out of 11 (55%) patients taking cannabis derivatives reported some positive effects with improved sleep and general wellbeing being most commonly reported. Patients reported spending between £10-£300 per month with an average of £42 per month. Cannabis products were obtained via the internet or from friends. Conclusion This small cohort of patients indicates that a significant proportion of glioblastoma patients investigate and use alternative therapies, in particular cannabis oil. NICE guidance for clinicians simply notes there is insufficient evidence to support the use of cannabis oil in the treatment of this disease. Given the publicity and interest in the utility of cannabis oil to treat cancers this leaves patients to research the use of these agents without access to robust clinical data to guide their use or indeed to conclude they are not beneficial. The accessing of these compounds, potentially by a sizeable number of patients, leaves them vulnerable to unregulated perhaps unscrupulous drug sources. This small study has further highlighted the unmet need for information and guidance on supplementary treatments for glioma patients and this poses a challenge to all those treating this group of patients to answer a question our patients are clearly wanting answered." @default.
• W3206757389 created "2021-10-25" @default.
• W3206757389 creator A5008764680 @default.
• W3206757389 creator A5068396955 @default.
• W3206757389 creator A5087784743 @default.
• W3206757389 date "2021-10-01" @default.
• W3206757389 modified "2023-10-18" @default.
• W3206757389 title "The use of cannabinoid and non-cannabinoid supplementary therapies in patients undergoing treatment for Glioblastoma reveals an urgent need for guidance" @default.
• W3206757389 doi "https://doi.org/10.1093/neuonc/noab195.023" @default.
• W3206757389 hasPublicationYear "2021" @default.
• W3206757389 type Work @default.
• W3206757389 sameAs 3206757389 @default.
• W3206757389 citedByCount "0" @default.
• W3206757389 crossrefType "journal-article" @default.
• W3206757389 hasAuthorship W3206757389A5008764680 @default.
• W3206757389 hasAuthorship W3206757389A5068396955 @default.
• W3206757389 hasAuthorship W3206757389A5087784743 @default.
• W3206757389 hasBestOaLocation W32067573891 @default.
• W3206757389 hasConcept C118552586 @default.
• W3206757389 hasConcept C121608353 @default.
• W3206757389 hasConcept C126322002 @default.
• W3206757389 hasConcept C143998085 @default.
• W3206757389 hasConcept C148001335 @default.
• W3206757389 hasConcept C170493617 @default.
• W3206757389 hasConcept C188816634 @default.
• W3206757389 hasConcept C2776895053 @default.
• W3206757389 hasConcept C2777056318 @default.
• W3206757389 hasConcept C2778938600 @default.
• W3206757389 hasConcept C2780427987 @default.
• W3206757389 hasConcept C2780871563 @default.
• W3206757389 hasConcept C2781100745 @default.
• W3206757389 hasConcept C71924100 @default.
• W3206757389 hasConcept C72563966 @default.
• W3206757389 hasConceptScore W3206757389C118552586 @default.
• W3206757389 hasConceptScore W3206757389C121608353 @default.
• W3206757389 hasConceptScore W3206757389C126322002 @default.
• W3206757389 hasConceptScore W3206757389C143998085 @default.
• W3206757389 hasConceptScore W3206757389C148001335 @default.
• W3206757389 hasConceptScore W3206757389C170493617 @default.
• W3206757389 hasConceptScore W3206757389C188816634 @default.
• W3206757389 hasConceptScore W3206757389C2776895053 @default.
• W3206757389 hasConceptScore W3206757389C2777056318 @default.
• W3206757389 hasConceptScore W3206757389C2778938600 @default.
• W3206757389 hasConceptScore W3206757389C2780427987 @default.
• W3206757389 hasConceptScore W3206757389C2780871563 @default.
• W3206757389 hasConceptScore W3206757389C2781100745 @default.
• W3206757389 hasConceptScore W3206757389C71924100 @default.
• W3206757389 hasConceptScore W3206757389C72563966 @default.
• W3206757389 hasIssue "Supplement_4" @default.
• W3206757389 hasLocation W32067573891 @default.
• W3206757389 hasLocation W32067573892 @default.
• W3206757389 hasOpenAccess W3206757389 @default.
• W3206757389 hasPrimaryLocation W32067573891 @default.
• W3206757389 hasRelatedWork W2032506781 @default.
• W3206757389 hasRelatedWork W2100328498 @default.
• W3206757389 hasRelatedWork W2413905430 @default.
• W3206757389 hasRelatedWork W2777311527 @default.
• W3206757389 hasRelatedWork W2794660688 @default.
• W3206757389 hasRelatedWork W2904170302 @default.
• W3206757389 hasRelatedWork W2982102370 @default.
• W3206757389 hasRelatedWork W3206757389 @default.
• W3206757389 hasRelatedWork W4212800886 @default.
• W3206757389 hasRelatedWork W4309553691 @default.
• W3206757389 hasVolume "23" @default.
• W3206757389 isParatext "false" @default.
• W3206757389 isRetracted "false" @default.
• W3206757389 magId "3206757389" @default.
• W3206757389 workType "article" @default.